Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome

Subhashie Wijemanne, Laura J.C. Wu, Joseph Jankovic

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Objectives: Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use. Methods: We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26-year period. Results: Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8±10.7 years (range, 4.1-70.2) and titrated to an optimal dose of 3.24±2.3 mg/day (range, 0.5-12.0), which was continued for an average of 2.6±3.2 years (range, 0.01-16.8). Marked to moderate improvement was noted in 211 (80.5%). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1%) patients. There were no cases of TD. Conclusions: Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalMovement Disorders
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Keywords

  • Fluphenazine
  • Side effects
  • Tardive dyskinesia
  • Tics
  • Tourette syndrome

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome'. Together they form a unique fingerprint.

  • Cite this